Brokerages expect that Alpine Immune Sciences Inc (NASDAQ:ALPN) will report $280,000.00 in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Alpine Immune Sciences’ earnings, with the highest sales estimate coming in at $300,000.00 and the lowest estimate coming in at $250,000.00. The firm is expected to report its next quarterly earnings report on Monday, March 16th.
According to Zacks, analysts expect that Alpine Immune Sciences will report full-year sales of $1.03 million for the current year, with estimates ranging from $860,000.00 to $1.16 million. For the next financial year, analysts forecast that the company will report sales of $1.10 million, with estimates ranging from $1.00 million to $1.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Alpine Immune Sciences.
Alpine Immune Sciences (NASDAQ:ALPN) last posted its earnings results on Wednesday, November 13th. The biotechnology company reported ($0.62) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.06. The company had revenue of $0.29 million for the quarter, compared to analysts’ expectations of $0.38 million.
ALPN has been the subject of several research analyst reports. Zacks Investment Research upgraded Alpine Immune Sciences from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a report on Thursday, November 28th. Piper Jaffray Companies decreased their price objective on Alpine Immune Sciences to $8.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th. They noted that the move was a valuation call. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Alpine Immune Sciences presently has an average rating of “Buy” and an average target price of $9.31.
A number of hedge funds have recently added to or reduced their stakes in ALPN. Jacobs Levy Equity Management Inc. purchased a new position in shares of Alpine Immune Sciences in the 2nd quarter worth $90,000. Hikari Power Ltd grew its position in Alpine Immune Sciences by 52.9% in the third quarter. Hikari Power Ltd now owns 185,587 shares of the biotechnology company’s stock worth $735,000 after acquiring an additional 64,224 shares in the last quarter. Vanguard Group Inc. grew its position in Alpine Immune Sciences by 67.7% in the second quarter. Vanguard Group Inc. now owns 202,582 shares of the biotechnology company’s stock worth $853,000 after acquiring an additional 81,800 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in Alpine Immune Sciences by 10.8% during the second quarter. Renaissance Technologies LLC now owns 106,261 shares of the biotechnology company’s stock worth $447,000 after acquiring an additional 10,400 shares during the last quarter. Institutional investors and hedge funds own 46.80% of the company’s stock.
Shares of NASDAQ:ALPN traded up $0.01 during mid-day trading on Friday, reaching $3.01. The stock had a trading volume of 1,474 shares, compared to its average volume of 28,149. The business’s 50 day moving average price is $2.89 and its 200 day moving average price is $3.98. Alpine Immune Sciences has a 1 year low of $2.25 and a 1 year high of $8.24. The company has a market cap of $55.58 million, a P/E ratio of -1.15 and a beta of 1.79. The company has a current ratio of 3.84, a quick ratio of 3.84 and a debt-to-equity ratio of 0.47.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.
Recommended Story: Trading Options- What is a Strangle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.